FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1694367148> ?p ?o ?g. }

• W1694367148 abstract "Chronic lymphocytic leukemia (CLL) is a hematologic malignancy derived from a clonal population of mature B-lymphocytes characterized by relatively low CD20 antigen expression. Although the disease often takes an indolent course, the majority of patients will eventually require therapy. Standard treatment for medically fit patients includes purine analogs and/or alkylating agents in addition to the type I anti-CD20 monoclonal antibody, rituximab. This therapy is inherently myelosuppressive and can result in significant morbidity and even mortality in patients with impaired performance status due to age and/or medical comorbidities. Historically, treatment options for the elderly or frail patient population were limited to mono-therapy with the oral alkylating agent, chlorambucil, rituximab, or another type I anti-CD20 monoclonal antibody ofatumumab. Recently, a newer-generation anti-CD20 monoclonal antibody, obinutuzumab, was developed for patients with CLL. Obinutuzumab is a humanized type II monoclonal antibody that appears to have more direct antibody-dependent cell-mediated cytotoxicity (ADCC) and possibly more direct cytotoxicity in vitro than previously available type I antibodies. A large Phase III prospective randomized clinical trial for older patients with impaired renal function and/or significant medical comorbidities demonstrated that when compared to conventionally-dosed rituximab and chlorambucil, the combination of chlorambucil and obinutuzumab administered at a dose and schedule involving early loading doses improved response rates and progression-free survival without significantly increasing toxicity. Results of this pivotal trial led to the FDA (US Food and Drug Administration) approval of obinutuzumab in combination with chlorambucil for frontline treatment of CLL. Obinutuzumab expands the armamentarium of active and less-toxic targeted agents in the evolving treatment landscape of CLL, providing physicians and patients with an additional therapeutic option." @default.
• W1694367148 created "2016-06-24" @default.
• W1694367148 creator A5006235077 @default.
• W1694367148 creator A5011922168 @default.
• W1694367148 date "2015-08-01" @default.
• W1694367148 modified "2023-09-26" @default.
• W1694367148 title "Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia" @default.
• W1694367148 cites W1545944104 @default.
• W1694367148 cites W1947577433 @default.
• W1694367148 cites W1973919081 @default.
• W1694367148 cites W1988217711 @default.
• W1694367148 cites W2015776299 @default.
• W1694367148 cites W2016955385 @default.
• W1694367148 cites W2029850226 @default.
• W1694367148 cites W2042725832 @default.
• W1694367148 cites W2047982141 @default.
• W1694367148 cites W2073873436 @default.
• W1694367148 cites W2091057822 @default.
• W1694367148 cites W2099145932 @default.
• W1694367148 cites W2100595321 @default.
• W1694367148 cites W2116262245 @default.
• W1694367148 cites W2120319857 @default.
• W1694367148 cites W2121227413 @default.
• W1694367148 cites W2124575836 @default.
• W1694367148 cites W2125134816 @default.
• W1694367148 cites W2126442701 @default.
• W1694367148 cites W2135270635 @default.
• W1694367148 cites W2140606816 @default.
• W1694367148 cites W2141139539 @default.
• W1694367148 cites W2142963736 @default.
• W1694367148 cites W2143901303 @default.
• W1694367148 cites W2144617723 @default.
• W1694367148 cites W2159970259 @default.
• W1694367148 cites W2163348695 @default.
• W1694367148 cites W2326175431 @default.
• W1694367148 cites W2101252134 @default.
• W1694367148 doi "https://doi.org/10.2147/ott.s68770" @default.
• W1694367148 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4562745" @default.
• W1694367148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26366093" @default.
• W1694367148 hasPublicationYear "2015" @default.
• W1694367148 type Work @default.
• W1694367148 sameAs 1694367148 @default.
• W1694367148 citedByCount "1" @default.
• W1694367148 countsByYear W16943671482017 @default.
• W1694367148 crossrefType "journal-article" @default.
• W1694367148 hasAuthorship W1694367148A5006235077 @default.
• W1694367148 hasAuthorship W1694367148A5011922168 @default.
• W1694367148 hasBestOaLocation W16943671481 @default.
• W1694367148 hasConcept C126322002 @default.
• W1694367148 hasConcept C143998085 @default.
• W1694367148 hasConcept C159654299 @default.
• W1694367148 hasConcept C18031839 @default.
• W1694367148 hasConcept C203014093 @default.
• W1694367148 hasConcept C2776694085 @default.
• W1694367148 hasConcept C2776755627 @default.
• W1694367148 hasConcept C2777607594 @default.
• W1694367148 hasConcept C2777866208 @default.
• W1694367148 hasConcept C2777938653 @default.
• W1694367148 hasConcept C2778461978 @default.
• W1694367148 hasConcept C2779338263 @default.
• W1694367148 hasConcept C2780653079 @default.
• W1694367148 hasConcept C2908647359 @default.
• W1694367148 hasConcept C40677261 @default.
• W1694367148 hasConcept C542903549 @default.
• W1694367148 hasConcept C71924100 @default.
• W1694367148 hasConcept C99454951 @default.
• W1694367148 hasConceptScore W1694367148C126322002 @default.
• W1694367148 hasConceptScore W1694367148C143998085 @default.
• W1694367148 hasConceptScore W1694367148C159654299 @default.
• W1694367148 hasConceptScore W1694367148C18031839 @default.
• W1694367148 hasConceptScore W1694367148C203014093 @default.
• W1694367148 hasConceptScore W1694367148C2776694085 @default.
• W1694367148 hasConceptScore W1694367148C2776755627 @default.
• W1694367148 hasConceptScore W1694367148C2777607594 @default.
• W1694367148 hasConceptScore W1694367148C2777866208 @default.
• W1694367148 hasConceptScore W1694367148C2777938653 @default.
• W1694367148 hasConceptScore W1694367148C2778461978 @default.
• W1694367148 hasConceptScore W1694367148C2779338263 @default.
• W1694367148 hasConceptScore W1694367148C2780653079 @default.
• W1694367148 hasConceptScore W1694367148C2908647359 @default.
• W1694367148 hasConceptScore W1694367148C40677261 @default.
• W1694367148 hasConceptScore W1694367148C542903549 @default.
• W1694367148 hasConceptScore W1694367148C71924100 @default.
• W1694367148 hasConceptScore W1694367148C99454951 @default.
• W1694367148 hasLocation W16943671481 @default.
• W1694367148 hasLocation W16943671482 @default.
• W1694367148 hasLocation W16943671483 @default.
• W1694367148 hasLocation W16943671484 @default.
• W1694367148 hasOpenAccess W1694367148 @default.
• W1694367148 hasPrimaryLocation W16943671481 @default.
• W1694367148 hasRelatedWork W1680113137 @default.
• W1694367148 hasRelatedWork W1768515905 @default.
• W1694367148 hasRelatedWork W1796006501 @default.
• W1694367148 hasRelatedWork W1971176848 @default.
• W1694367148 hasRelatedWork W1996134582 @default.
• W1694367148 hasRelatedWork W2023606875 @default.
• W1694367148 hasRelatedWork W2034398106 @default.
• W1694367148 hasRelatedWork W2073139359 @default.
• W1694367148 hasRelatedWork W2128340646 @default.
• W1694367148 hasRelatedWork W2143715586 @default.

• next